AusBiotech says the industry should not be made to pay for the TGA's digital transformation through increases to cost recovery fees.
AusBiotech says it cannot support new reason for higher cost-recovery fees
March 1, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
A hearing that provided more evidence of the need for meaningful change
October 29, 2026 - - Latest News -
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026 - - Latest News -
Rebates and net spend are the major PBS story of the past decade
October 28, 2026 - - Latest News -
Astellas bets up to US$1.34 billion on Melbourne startup's cancer candidate
October 28, 2026 - - Latest News -
Managing an agreement negotiation as a 'prisoner of circumstance'
October 28, 2026 - - Latest News -
Lung scarring killing 11 Australians a day, with one in five cases traced to work
October 28, 2026 - - Latest News -
The stakes are very high on access in a contested budget environment
October 28, 2026 - - Latest News
